| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1103931771 |
| P356 | DOI | 10.1038/S41388-018-0283-3 |
| P698 | PubMed publication ID | 29755129 |
| P50 | author | Urszula L McClurg | Q56427069 |
| Arash Nabbi | Q57008801 | ||
| Joanne Edwards | Q42315840 | ||
| P2093 | author name string | Craig N Robson | |
| Karl T Riabowol | |||
| Sirintra Nakjang | |||
| Mahsa Azizyan | |||
| Stuart R McCracken | |||
| Nay C T H Chit | |||
| P2860 | cites work | PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms | Q24300933 |
| SETD6 monomethylates H2AZ on lysine 7 and is required for the maintenance of embryonic stem cell self-renewal | Q24309465 | ||
| Defining the human deubiquitinating enzyme interaction landscape | Q24315885 | ||
| Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor | Q24631156 | ||
| Deubiquitinating enzymes as oncotargets | Q27026189 | ||
| A conserved two-step binding for the UAF1 regulator to the USP12 deubiquitinating enzyme | Q27728092 | ||
| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 | ||
| Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer | Q28075965 | ||
| WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex | Q28115820 | ||
| Allosteric Activation of Ubiquitin-Specific Proteases by β-Propeller Proteins UAF1 and WDR20 | Q28117407 | ||
| Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase | Q28511501 | ||
| p53 coordinates base excision repair to prevent genomic instability | Q28834500 | ||
| Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 | Q29547403 | ||
| HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
| STAR: ultrafast universal RNA-seq aligner | Q29615052 | ||
| The development of androgen-independent prostate cancer | Q29615650 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Transcriptional control of human p53-regulated genes | Q29617650 | ||
| Pathview: an R/Bioconductor package for pathway-based data integration and visualization | Q30641811 | ||
| Gene ontology analysis for RNA-seq: accounting for selection bias | Q33861598 | ||
| Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. | Q33873915 | ||
| A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus | Q33944754 | ||
| Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer | Q34313778 | ||
| Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers | Q34504751 | ||
| Awakening guardian angels: drugging the p53 pathway | Q35014385 | ||
| Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression | Q35223274 | ||
| Cheminformatics models based on machine learning approaches for design of USP1/UAF1 abrogators as anticancer agents | Q35593976 | ||
| Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value | Q35709269 | ||
| Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells | Q35934305 | ||
| USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance | Q36367391 | ||
| Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer | Q38262067 | ||
| Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression | Q38353894 | ||
| Gene amplifications associated with the development of hormone-resistant prostate cancer | Q38450128 | ||
| Gene silencing of USP1 by lentivirus effectively inhibits proliferation and invasion of human osteosarcoma cells | Q38731335 | ||
| Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer | Q38768101 | ||
| Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance | Q38798223 | ||
| High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models | Q38956648 | ||
| Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway. | Q38957082 | ||
| Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor. | Q39093258 | ||
| USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells | Q39377739 | ||
| The USP1/UAF1 complex promotes double-strand break repair through homologous recombination | Q39560571 | ||
| FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. | Q39803380 | ||
| Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. | Q40114067 | ||
| Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation | Q40550797 | ||
| Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. | Q42146513 | ||
| Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity | Q42291797 | ||
| Mdm2 association with p53 targets its ubiquitination | Q42824389 | ||
| Pleckstrin Homology (PH) Domain Leucine-rich Repeat Protein Phosphatase Controls Cell Polarity by Negatively Regulating the Activity of Atypical Protein Kinase C. | Q46874998 | ||
| Observer variation in immunohistochemical analysis of protein expression, time for a change? | Q53004389 | ||
| Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. | Q53762730 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4679-4691 | |
| P577 | publication date | 2018-05-14 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12 | |
| P478 | volume | 37 |
| Q90113755 | Differential Expression of DUB Genes in Ovarian Cells Treated with Di-2-Ethylhexyl Phthalate |
| Q64076898 | Interaction of the Human Papillomavirus E1 Helicase with UAF1-USP1 Promotes Unidirectional Theta Replication of Viral Genomes |
| Q104142418 | Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets |
| Q90608540 | Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy |
| Q55129906 | The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival. |
| Q103027967 | UAF1 deubiquitinase complexes facilitate NLRP3 inflammasome activation by promoting NLRP3 expression |
Search more.